Drugs and patents in ATC class A10BB

Subscribe to access the full database, or Start Trial
Tradename	Generic Name
CHLORPROPAMIDE	chlorpropamide
DIABINESE	chlorpropamide
GLUCAMIDE	chlorpropamide
ORINASE	tolbutamide
TOLBUTAMIDE	tolbutamide
ORINASE DIAGNOSTIC	tolbutamide sodium
>Tradename	>Generic Name

Last updated: January 8, 2026

Executive Summary

The ATC classification A10BB encompasses sulfonylureas — a major class of oral hypoglycemic agents used predominantly in managing type 2 diabetes mellitus (T2DM). With an evolving market driven by demographic shifts, technological advancements, regulatory policies, and patent expirations, understanding current and future market dynamics is vital for industry stakeholders. This report analyzes the sulfonylurea landscape, highlighting patent trends, competitive positioning, market drivers, challenges, and policy frameworks shaping the segment.

Overview of A10BB - Sulfonylureas

Definition and Mechanism of Action

Sulfonylureas constitute a class of oral medications that stimulate pancreatic beta-cell insulin secretion by closing ATP-sensitive potassium channels, thereby lowering blood glucose levels ([3], [4]).

Common Drugs	Generic Name	Patent Status	Year Introduced	Market Share (2022)
Glibenclamide	Glyburide	Patent expired	1969	25%
Glipizide	Glucotrol	Patent expired	1984	20%
Glimepiride	Amaryl	Patent protected (expires 2027)	1995	15%
Gliquidone	Gliquidone	Generic	1982	5%
Tolbutamide	Tolbutamide	Patent expired	1957	10%

Key Attributes

Well-established as first-line in some guidelines.
Cost-effective, especially in emerging markets.
Often combined with other antihyperglycemic agents for synergistic effects.

Market Dynamics of Sulfonylureas

Market Size and Growth Trends

Global Market Valuation (2022): Estimated at USD 1.4 billion ([1]).
Compound Annual Growth Rate (CAGR): Projected at 5.2% from 2022 to 2030 ([2]).
Forecast Drivers:
- Rising prevalence of T2DM (~537 million adults in 2021; expected to reach 643 million by 2030).
- Increasing use in low- and middle-income countries due to affordability.
- Growing awareness and diagnosis.

Market Drivers

Driver	Impact	Source
Diabetes Prevalence Increase	Expanding patient base	[2]
Cost-Effectiveness	Adoption in resource-limited settings	[1]
Established Efficacy & Safety	Preference in clinical practice	[3]
Patent Expirations	Increased generic competition, lowering prices	[4]

Market Challenges

Challenge	Impact	Source
Risk of Hypoglycemia	Leads to cautious prescribing	[4]
Cardiac Risks	Particularly with specific agents	[3]
Competition from Newer Agents	DPP-4 inhibitors, SGLT2 inhibitors	[5]
Patent Expiry and Generic Entry	Margin compression	[4]

Patent Landscape of Sulfonylureas

Patent Timeline and Trends

Drug	Original Patent Filing	Patent Expiry	Patent Status (2023)	Key Patent Applicants	Notes
Glyburide	1968	1990s	Expired	Eli Lilly, others	Generics dominate
Glipizide	Early 1980s	2000s	Expired	Abbott, others	Widely genericized
Glimepiride	1995	2027	Active	Sanofi	Patent protection ongoing
Gliquidone	1982	Not applicable	Generic	Various	No recent patent filings

Innovation Activities and Patent Filings

R&D Focus:
- Improved formulations for reduced hypoglycemia.
- Fixed-dose combinations (FDCs) with other agents.
- Novel delivery systems (e.g., sustained release).
Patent Filing Trends:
- Significant activity until early 2010s.
- Patent applications peaked around 2000–2010.
- Post-2015: decline in new patent filings, primarily due to patent expirations.

Impact of Patent Expiries

Entry of generics post-patent expiry increased market competition.
Price erosion in mature markets.
Innovation shifted toward combination therapies and new drug classes.

Competitive Landscape

Key Companies	Market Share (2022)	Core Focus	Notable Patents	Strategic Moves
Sanofi	15%	Glimepiride	Patent till 2027	Focusing on combination therapies
Eli Lilly	12%	Glyburide	Expired	Focus on newer agents
Novo Nordisk	10%	Partnerships	Not active in sulfonylureas	Emphasizes insulin and GLP-1 analogs
Generic Manufacturers	35%	Generics	Numerous expired patents	Price competition

Policy and Regulatory Factors

Stringent regulation on hypoglycemia risk management.
Inclusion in WHO Essential Medicines List.
Patent linkage policies influence market entry and pricing.
Accelerated approval pathways for formulations with improved safety profiles.

Comparisons with Other Antidiabetic Classes

Parameter	Sulfonylureas (A10BB)	DPP-4 Inhibitors	SGLT2 Inhibitors	GLP-1 Receptor Agonists
Cost	Low	High	High	Very High
Efficacy	Moderate	Moderate	High	Very High
Hypoglycemia Risk	Higher	Lower	Lower	Lower
Patent Durability	Long	Protects ~2024-2027	Protects ~2029	Protects ~2028

Future Outlook

Emerging Trends

Innovative formulations: sustained-release, combination FDCs.
Regulatory focus: safety profiles, especially hypoglycemia.
Digital integration: monitoring compliance via digital health tools.
Market expansion: emerging economies to remain major growth markets.

Anticipated Market Changes (Next 5–10 Years)

Patent expirations for key drugs like Glimepiride in 2027 will accelerate generic penetration.
Incremental innovation: low-level modifications to prolong patent life via “evergreening” strategies.
Competition from newer classes may limit growth but sustain demand due to affordability.

Key Challenges and Opportunities

Challenges	Opportunities	Strategic Implications
Patent cliff	Diversification into combination therapies	Invest in R&D for FDCs
Safety concerns	Development of safer formulations	Emphasize clinical safety data
Competitive generic landscape	Cost leadership	Focus on affordability and access
Growing competition from newer drugs	Partner with innovative biotech	Expand product pipeline

Key Takeaways

Sulfonylureas remain a cost-effective, widely adopted class for T2DM management, especially in emerging markets.
Patent expirations have significantly increased generic competition, pressing prices downward.
Innovation activity has shifted towards combination FDCs and formulations with improved safety profiles.
Regulatory policies and patent landscapes will continue to influence market dynamics, with upcoming patent expiries in 2027 potentially reshaping the competitive landscape.
The segment faces competition from newer, incretin-based and SGLT2 inhibitor drugs, but affordability sustains sulfonylureas' relevance.

FAQs

Q1: What is the main factor driving the decline in sulfonylurea patents?
A1: The original patents on most first-generation sulfonylureas have expired, leading to widespread generic manufacturing and price competition.

Q2: How do patent expiries affect the market for sulfonylureas?
A2: Expirations enable generic companies to enter the market, significantly reducing prices, increasing accessibility, but also intensifying market competition.

Q3: Are sulfonylureas still recommended in clinical guidelines?
A3: Yes, especially in resource-limited settings due to their affordability and established efficacy, though newer agents are often preferred in developed markets for safety reasons.

Q4: What future patents could influence the sulfonylurea segment?
A4: Patent applications for novel formulations, combination therapies, or safety-enhanced versions may provide exclusivity beyond the original drugs’ expiries.

Q5: How does the safety profile of sulfonylureas compare to newer drug classes?
A5: Sulfonylureas carry a higher risk of hypoglycemia and weight gain compared to DPP-4 inhibitors and SGLT2 inhibitors, influencing prescribing patterns.

References

Grand View Research. (2022). Global Diabetes Drug Market Size, Share & Trends Analysis.
MarketsandMarkets. (2022). Diabetes Care Devices & Drugs Market Forecast.
American Diabetes Association. (2022). Standards of Medical Care in Diabetes.
U.S. Patent and Trademark Office (USPTO). Patent data, 2023.
IQVIA. (2022). Global Trends in Antidiabetic Drug Consumption.

Drugs in ATC Class A10BB

Drugs in ATC Class: A10BB - Sulfonylureas

Market Dynamics and Patent Landscape for ATC Class: A10BB - Sulfonylureas